[1] Mangiacapra F, De Bruyne B, Muller O, et al. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv, 2010; 3, 35-40. doi:  10.1016/j.jcin.2009.10.024
[2] Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA, 2011; 306, 1215-23. doi:  10.1001/jama.2011.1332
[3] Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J, 2009; 157, 818-24, 24 e1. doi:  10.1016/j.ahj.2009.02.012
[4] Chiu FC, Wang TD, Lee JK, et al. Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention. Eur J Intern Med, 2011; 22, 471-7. doi:  10.1016/j.ejim.2011.02.021
[5] Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation, 2009; 120, 2214-21. doi:  10.1161/CIRCULATIONAHA.109.883454
[6] Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol, 2007; 49, 1505-16. doi:  10.1016/j.jacc.2006.11.044
[7] Lev EI, Patel RT, Guthikonda S, et al. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP Ⅲa and response to aspirin and clopidogrel. Thromb Res, 2007; 119, 355-60. doi:  10.1016/j.thromres.2006.02.006
[8] Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009; 360, 363-75. doi:  10.1056/NEJMoa0808227
[9] Saydam F, Degirmenci I, Birdane A, et al. The CYP2C19*2 and CYP2C19*2017; 121, 29-36.
[10] Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation, 2009; 119, 2553-60. doi:  10.1161/CIRCULATIONAHA.109.851949
[11] Wallentin L, James S, Storey RF, et al. Effect of CYP2C19*2010; 376, 1320-8.
[12] Mayer K, Orban M, Bernlochner I, et al. Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets, 2015; 26, 53-8. doi:  10.3109/09537104.2013.863857
[13] Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest, 1996; 26, 353-70. doi:  10.1046/j.1365-2362.1996.150293.x
[14] Colombo A, Proietti R, Culic V, et al. Triggers of acute myocardial infarction: a neglected piece of the puzzle. J Cardiovasc Med, 2014; 15, 1-7. doi:  10.2459/JCM.0b013e3283641351
[15] Freeman K, Farrow S, Schmaier A, et al. Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. Am J Hypertens, 1995; 8, 863-9. doi:  10.1016/0895-7061(95)00155-I
[16] Peace AJ, Mangiacapra F, Bailleul E, et al. alpha2A-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant. Arterioscler Thromb Vasc Biol, 2014; 34, 1314-9. doi:  10.1161/ATVBAHA.114.303275
[17] Peace AJ, Tedesco AF, Foley DP, et al. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost, 2008; 6, 2027-34. doi:  10.1111/jth.2008.6.issue-12
[18] Cuisset T, Hamilos M, Delrue M, et al. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome. Thromb Haemost, 2010; 103, 774-9. doi:  10.1160/TH09-06-0355
[19] Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association for Percutaneous Cardiovascular I, Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J, 2010; 31, 2501-55. doi:  10.1093/eurheartj/ehq277
[20] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation, 2011; 124, e574-651. doi:  10.1161/CIR.0b013e31823ba622
[21] Hobson AR, Petley GW, Dawkins KD, et al. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets, 2007; 18, 497-505. doi:  10.1080/09537100701329162
[22] Yee DL, Sun CW, Bergeron AL, et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood, 2005; 106, 2723-9. doi:  10.1182/blood-2005-03-1290
[23] Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Eng J Med, 1985; 313, 1315-22. doi:  10.1056/NEJM198511213132103
[24] Andrews NP, Gralnick HR, Merryman P, et al. Mechanisms underlying the morning increase in platelet aggregation: a flow cytometry study. J Am Coll Cardiol, 1996; 28, 1789-95. doi:  10.1016/S0735-1097(96)00398-1
[25] Mustonen P, van Willigen G, Lassila R. Epinephrine-via activation of p38-MAPK--abolishes the effect of aspirin on platelet deposition to collagen. Thromb Res, 2001; 104, 439-49. doi:  10.1016/S0049-3848(01)00388-7
[26] Keularts IM, van Gorp RM, Feijge MA, et al. alpha(2A)-adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels. J Biol Chem, 2000; 275, 1763-72. doi:  10.1074/jbc.275.3.1763
[27] Maayani S, Schwarz T, Craddock-Royal B, et al. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro. Platelets, 2001; 12, 359-75. doi:  10.1080/09537100120078403
[28] Beres BJ, Toth-Zsamboki E, Vargova K, et al. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thromb Haemost, 2008; 100, 829-38. https://www.ncbi.nlm.nih.gov/pubmed/?term=Analysis+of+platelet+alpha2-adrenergic+receptor+activity+in+stable+coronary+artery+disease+patients+on+dual+antiplatelet+therapy.
[29] Kiive E, Kurrikoff T, Maestu J, et al. Effect of alpha2A-adrenoceptor C-1291G genotype and maltreatment on hyperactivity and inattention in adolescents. Prog Neuro-psychopharmacol Biol Psychiatry, 2010; 34, 219-24. doi:  10.1016/j.pnpbp.2009.11.011
[30] Tamm G, Kreegipuu K, Harro J. Perception of emotion in facial stimuli: The interaction of ADRA2A and COMT genotypes, and sex. Prog Neuro-psychopharmacol Biol Psychiatry, 2016; 64, 87-95. doi:  10.1016/j.pnpbp.2015.07.012
[31] Yee DL, Bergeron AL, Sun CW, et al. Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost, 2006; 4, 2043-50. doi:  10.1111/jth.2006.4.issue-9